Second-quarter 2026 results $12.6B ↑4.8%1 On a comparable basis* Worldwide sales Adjusted diluted EPS $1.312 Exceeded the midpoint of our guidance and the consensus estimate Full-year 2026 guidance3 Rearmed comparable sales growth guidance range of 6.5% to 7.5% Key business units | Second-quarter sales Raised adjusted diluted EPS guidance range to $5.45 to $5.60 Diagnostics $3.1B $5.9B $2.1B Nutrition Medical Devices Established Pharmaceuticals $1.5B Second-quarter business highlights Leadership in noninvas ...